Evidence map›Paper›PMID 38451247›Full record

ReviewThe Journal of infectious diseases2024

HIV Diagnostics and Vaccines: It Takes Two to Tango.

Will Colón, Valérie Oriol-Mathieu, John Hural, Lucy Hattingh, Ferdinard Adungo, Ole Lagatie, Ludo Lavreys, Mary Allen, Omu Anzala, Nicole Espy and 10 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 7 countries.

Will ColónJohnson & Johnson Global Public Health Research and Development, Beerse, Belgium.
Valérie Oriol-MathieuJanssen Vaccines and Prevention B.V., Leiden, the Netherlands.ORCID 0000-0003-4734-1729
John HuralVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Lucy HattinghLH Consulting, Berkeley, California.
Ferdinard AdungoKenya Medical Research Institute, Nairobi, Kenya.ORCID 0000-0002-0873-7993
Ole LagatieJohnson & Johnson Global Public Health Research and Development, Beerse, Belgium.
Ludo LavreysJanssen Vaccines and Prevention B.V., Leiden, the Netherlands.
Mary AllenNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Omu AnzalaKenya Aids Vaccine Initiative Institute of Clinical Research, University of Nairobi, Kenya.
Nicole EspyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Katrien FransenHIV/STD Reference Laboratory, Clinical Virology Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Patricia J GarciaEpidemiology, STD, and HIV Unit, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru.
Milton MacielNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Maurine MurtaghThe Murtagh Group, LLC, Woodside, California.
Sheila A PeelDiagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland.
Rosanna W PeelingClinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Litjen L J TanImmunize.org, Saint Paul, Minnesota.
Mitchell WarrenAVAC, New York, New York.
Maria Grazia PauJanssen Vaccines and Prevention B.V., Leiden, the Netherlands.
Patricia M D'SouzaNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Human Vaccines Project Europe · NLNational Institutes of Health · USFred Hutch Cancer Center · USJohnson & Johnson (United States) · USInstituut voor Tropische Geneeskunde · BEKenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBUniversidad Peruana Cayetano Heredia · PEUniversity of Nairobi · KEWalter Reed Army Institute of Research · US

Funding

Janssen Pharmaceutica NVJanssen Vaccines & Prevention B.V.
6 · The paper itself

Abstract

Current serologic tests for HIV screening and confirmation of infection present challenges to the adoption of HIV vaccines. The detection of vaccine-induced HIV-1 antibodies in the absence of HIV-1 infection, referred to as vaccine-induced seropositivity/seroreactivity, confounds the interpretation of test results, causing misclassification of HIV-1 status with potential affiliated stigmatization. For HIV vaccines to be widely adopted with high community confidence and uptake, tests are needed that are agnostic to the vaccination status of tested individuals (ie, positive only for true HIV-1 infection). Successful development and deployment of such tests will require HIV vaccine developers to work in concert with diagnostic developers. Such tests will need to match today's high-performance standards (accuracy, cost-effectiveness, simplicity) for use in vaccinated and unvaccinated populations, especially in low- and middle-income countries with high HIV burden. Herein, we discuss the challenges and strategies for developing modified serologic HIV tests for concurrent deployment with HIV vaccines.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsHIV AntibodiesHumansSerologic TestsAIDS VaccinesHIV AntibodiesantibodiesdiagnosticsHIVvaccinevaccine-induced seropositivity/seroreactivity

Identifiers

PMID38451247
PMCPMC11492280
OpenAlexW4392546021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.